Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-07-03 Neuropathic pain
| Amitriptyline |
|
Formulary
|
Tablets 10mg, 25mg, 50mg Use in line with NICE and LSCMMG guidelines. |
|
| Duloxetine |
|
Formulary
|
There can be variation in the licensing of different medicines containing the same drug. |
|
|
| Ketamine oral solution |
|
Formulary
|
Liquid 50mg/5mL For chronic pain - Prescribing retained within NHS commissioned specialist pain services in Lancashire and South Cumbria.
|
|
Unlicensed| Lidocaine |
|
Formulary
|
5% Medicated Plasters Post Herpetic Neuralgia
Any off label use must be on the advice of the acute pain team and must only be prescribed by secondary care. |
 LSCMMG: Lidocaine 5% Medicated Plasters Post-Herpetic Neuralgia NMR LSCMMG: Lidocaine for the treatment of localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents NMR |
|
|
For off-label indications. | Nortriptyline |
|
Formulary
|
Tablets 10mg, 25mg Use in line with NICE and LSCMMG guidelines.
|
|
LSCMMG: Nortriptyline tablets (10mg and 25mg) NMR |
|
| Pregabalin |
|
Formulary
|
Capsules 25mg, 50mg, 75mg, 100mg, 150mg, 200mg Use in line with NICE and LSCMMG guidelines. |
 MHRA: Antiepileptics: risk of suicidal thoughts and behaviour MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy MHRA: Pregabalin (Lyrica): reports of severe respiratory depression |
|
|
Links
- LSCMMG: ADHD combined adult and child shared care guideline
- LSCMMG: Chronic Pain Patient Resources: Managing Opioid Medication
- LSCMMG: Chronic Pain Prescriber Resources
- LSCMMG: Headache Management Guideline For Adults
- LSCMMG: Lidocaine 5% Medicated Plasters Post-Herpetic Neuralgia NMR
- LSCMMG: Lidocaine for the treatment of localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents NMR
- LSCMMG: Neuropathic Pain: Primary Care Management
- LSCMMG: Nortriptyline tablets (10mg and 25mg) NMR
- LSCMMG: Opioid reduction: best interests opioid reduction position statement
- LSCMMG: Opioid treatment: patient-prescriber opioid treatment agreement
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2022: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA Drug Safety Update Feb 2021: Pregabalin (Lyrica): reports of severe respiratory depression
- MHRA Drug Safety Update Oct 2017: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Antiepileptics: risk of suicidal thoughts and behaviour
- MHRA: Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions
- MHRA: Gabapentin (Neurontin): risk of severe respiratory depression
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April
- MHRA: Pregabalin (Lyrica): findings of safety study on risks during pregnancy
- MHRA: Pregabalin (Lyrica): reports of severe respiratory depression
- NICE CG150: Headaches in over 12s: diagnosis and management
- NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings
- NICE CG59: Low back pain and sciatica in over 16s: assessment and management
- NICE NG180: Perioperative care in adults
- NICE NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain
- NICE Unlicensed medicine review 27: Ketamine for chronic pain